Major readouts on the horizon for small developers
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Novartis trims its pipeline
Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.
Anthos doubles down on its novel blood thinner
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
After 33 years Geron could have an approved drug
Imetelstat survives a US clinical hold and a terminated alliance with J&J to score in its pivotal Imerge study.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
